Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Given Average Rating of “Moderate Buy” by Analysts

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $17.20.

SENS has been the topic of several research analyst reports. Weiss Ratings cut Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Stifel Nicolaus decreased their target price on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Monday, May 11th. HC Wainwright lowered their target price on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Mizuho lowered their target price on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other news, Director Douglas A. Roeder acquired 22,686 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the acquisition, the director directly owned 144,635 shares of the company’s stock, valued at $804,170.60. The trade was a 18.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at about $68,000. GSK plc bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. Townsend Asset Management Corp NC ADV purchased a new stake in Senseonics Holdings, Inc. Common Stock during the fourth quarter valued at approximately $60,000. Cetera Investment Advisers purchased a new stake in Senseonics Holdings, Inc. Common Stock during the first quarter valued at approximately $85,000. Finally, Sanctuary Advisors LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at approximately $71,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Holdings, Inc. Common Stock Price Performance

Senseonics Holdings, Inc. Common Stock stock opened at $5.11 on Friday. The stock has a market cap of $213.60 million, a PE ratio of -2.56 and a beta of 0.99. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.51. Senseonics Holdings, Inc. Common Stock has a 1 year low of $4.79 and a 1 year high of $12.51. The firm has a 50-day moving average of $6.11.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last issued its earnings results on Thursday, May 7th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.The company had revenue of $11.71 million for the quarter. Research analysts expect that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current year.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.